Momentum Stock Watch: Endologix, Inc. (ELGX)

Company Profile:

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system; VELA Proximal Endograft; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Recent News:

On Feb. 5, 2018, Endologix, Inc. (ELGX) announced the completion of enrollment in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study.

The company will report financial results for the fourth quarter and fiscal year 2017 after the market close on Wednesday, February 21, 2018. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

For the third quarter ended September 30, 2017, the company reported Gross profit was $29.1 million, compared to a gross profit of $36.9 million in the third quarter of 2016. Net loss for the third quarter of 2017 was $14.3 million, or $(0.17) per share, compared to a net loss of $15.2 million, or $(0.18) per share, a year ago.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



ELGX’s strengths can be seen in its strong growth and better efficiency compared with its peers.. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic Oscillator and RSI stands at 49.95 with positive bias. We rate Endologix, Inc. (ELGX) a STRONG BUY.

About the Author

has written 9650 stories on this site.

Copyright © 2012 Nine Stocks